Skip to content

Effect of phenylephrine versus ephedrine on the incidence of postoperative delirium in elderly adults undergoing non-cardiac and non-neurosurgical procedures

Effect of phenylephrine versus ephedrine on the incidence of postoperative delirium in elderly adults undergoing non-cardiac and non-neurosurgical procedures

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115385
Enrollment
Unknown
Registered
2025-12-25
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Delirium

Interventions

Phenylephrine group:During surgery, a continuous infusion of phenylephrine at a concentration of 0.1 mg/mL was administered intravenously. The infusion was initiated at the start of anesthesia inducti
Ephedrine group:During surgery, a continuous infusion of ephedrine at a concentration of 2 mg/mL was administered intravenously. The infusion was initiated at the start of anesthesia induction and adj

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years; 2. Elective surgery under general anesthesia, excluding cardiac and neurosurgical procedures; 3. Major surgery with an anticipated duration > 2 hours; 4. ASA physical status classification I–III.

Exclusion criteria

Exclusion criteria: 1. Use of other vasoactive drugs during surgery (e.g., norepinephrine, dopamine, epinephrine); 2. History of stroke, Parkinson’s disease, or epilepsy; 3. Language impairment or significant hearing or visual deficits preventing communication; 4. Depression, generalized anxiety disorder, or schizophrenia; 5. Severe cardiovascular disease, with NYHA class >= III cardiac function; 6. Severe hepatic dysfunction, Child-Pugh class C; 7. Severe renal insufficiency requiring preoperative renal replacement therapy; 8. Alcohol abuse, psychological disorders, or non-compliant patients; 9. Participation in other clinical trials.

Design outcomes

Primary

MeasureTime frame
The incidence of POD from postoperative day 1 to day 7;

Secondary

MeasureTime frame
Severity of POD;Postoperative pain scores ;Number of patients admitted to the ICU and ICU length of stay;Postoperative hospital length of stay;Postoperative in-hospital adverse cardiovascular and cerebrovascular events, such as myocardial infarction, arrhythmia, heart failure, and cerebral infarction.;All-cause mortality within 30 days postoperatively;

Countries

China

Contacts

Public ContactWang Yulan

The First Affiliated Hospital of Soochow University

wylsdfyy@163.com+86 138 6257 1452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 17, 2026